SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Parenteral Drugs (India) Ltd (PDPL)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524689 NSE: PDPL Pharmaceuticals & Drugs | Small Cap | Parenteral Drugs Share Price

₹3.39 0.00 (0.00%)

As on 21-Aug'23 18:01

Parenteral Drugs (India) Ltd (PDPL)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524689 NSE: PDPL Pharmaceuticals & Drugs | Small Cap | Parenteral Drugs Share Price

₹3.39 0.00 (0.00%)

As on 21-Aug'23 18:01

Key Metrics
Valuation Multiples
Market Cap
₹10 Cr.
Current Price
₹3.4
52-Week Low / High
₹3 / 3
TTM EPS
₹-25.6
TTM Sales
₹8.5 Cr.
Book Value per Share
₹-278.9
P/E Ratio
0.00
Industry PE
50
Price to Book (P/B)
-0.01
In line with its 5-year historical median
Price to Sales (P/S)
1.19
In line with its 5-year historical median
EV/EBITDA
-43.15
In line with its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
0.00%
Return on Capital Employed (ROCE)
0.00%
Return on Assets (ROA)
-29.75%
Operating Profit Margin
-96.7%
Net Profit Margin
-1000.3%
Gross Profit Margin
-1,127.1%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-61.81%
Operating Profit Growth (1 Year)
-
-
Net Profit Growth (1 Year)
-
-
Asset Quality
Promoter Holding
73.29%
Pledged shares (%) of Promoter's holding (%)
94.50%
Reserves
₹-861 Cr.
Equity
₹29.8 Cr.
Face Value
₹10
All Time Low / High
₹0.38 / 399.95

Parenteral Drugs (India) stock performance

Key Ratios
mw4me loader

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Parenteral Drugs (India) Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
ROCE % -0.7%-7%-0.1%-1.9%-11%-10.8%-10.5%-44.3%-53.4%0%-
Value Creation
Index
-1.1-1.5-1.0-1.1-1.8NANANANANA-

Growth Parameters

Sales 22318718717614952.23333.231.912.29
Sales YoY Gr.--15.9%-0.4%-5.7%-15.4%-64.9%-36.9%0.8%-4%-61.8%-
Adj EPS -18.4-32.9-19.7-18.1-36-37.4-31.8-49.6-38.3-40.8-25.6
YoY Gr.-NANANANANANANANANA-
BVPS (₹) 97.875.649.731.54.4-92.2-124.5-174.2-212.5-253.3-278.9
Adj Net
Profit
-47.7-85.1-58.7-54-107-112-94.9-148-114-122-76
Cash Flow from Ops. -4.5-156-21.4-4.831.4121148456112125-
Debt/CF from Ops. -59.7-2.3-19.6-95.117.95.34.31.45.75.1-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales -27.6%-39.4%-28.3%-61.8%
Adj EPS NANANANA
BVPS-211.2%-325.3%NANA
Share Price -20.2% -7% -1.9% -

Key Financial Parameters

Mar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21TTM
Return on
Equity %
-15.6-34.2-31.9-40.7-54.3-80.3158.853.322.619.69.6
Op. Profit
Mgn %
3.9-11.8-21.67.3-31.1-64.4-42.8-49.6-46.1-96.8-175.8
Net Profit
Mgn %
-21.4-45.4-31.5-30.7-72.1-213.6-287.8-445.4-357.9-1000.3-898.5
Debt to
Equity
11.72.64.321.5-2.3-1.7-1.2-1-0.8-
Working Cap
Days
2813003213713706518048058582,2801,481
Cash Conv.
Cycle
105125198258254482255-10-32-29-25,423

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21
Sales222.56187.22186.51175.89148.7852.2132.9533.2131.8712.17
Operating Expenses + 214209.49226.71163.18196.1889.5048.9049.6746.5623.94
Manufacturing Costs2028.2431.8922.3713.7716.2214.6017.9616.361.65
Material Costs114.37117.39105.5479.05123.1926.026.766.466.325.66
Employee Cost 19.8817.3621.5518.4411.8015.1116.7019.9419.2114.51
Other Costs 59.7646.5067.7243.3247.4232.1410.845.314.672.11
Operating Profit 8.56-22.27-40.2012.71-47.40-37.29-15.94-16.46-14.68-11.77
Operating Profit Margin (%) 3.8%-11.9%-21.6%7.2%-31.9%-71.4%-48.4%-49.6%-46.1%-96.7%
Other Income + 0.280.1457.120.701.915.261.450.240.250.06
Exceptional Items 000-0.41-0.54-0.100000
Interest 39.1942.2254.2459.1758.0173.9486.3496.05109.96125.44
Depreciation 12.8417.3417.7023.8517.0619.1018.5769.1217.3517.33
Profit Before Tax -43.20-81.70-55.03-70.02-121.11-125.16-119.40-181.39-141.73-154.47
Tax 4.613.503.68-15.94-12.61-11.08-23.31-33.49-27.66-32.76
Profit After Tax -47.82-85.20-58.70-54.08-108.49-114.09-96.09-147.90-114.07-121.71
PAT Margin (%) -21.5%-45.5%-31.5%-30.8%-72.9%-218.0%-291.0%-445.0%-357.0%-1,000.3%
Adjusted EPS (₹)-18.5-32.9-19.7-18.1-36.4-38.3-32.2-49.6-38.3-40.8
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Parenteral Drugs - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21

Equity and Liabilities

Shareholders Fund + 260.51208.54159.82105.73289.42-11.66-107.78-447.25-561.63-683.20
Share Capital 32.3337.7440.3540.3542.8529.8229.8229.8229.8229.82
Reserves 228.19170.80119.4765.38246.57-41.48-137.59-477.07-591.45-713.02
Debt +270.48355.80395.20411.06505.48530.02468.45108.71106.24106.24
Long Term Debt149.52305.54326.97329.76377.60402.08340.52108.71106.24106.24
Short Term Debt120.9750.2668.2381.30127.87127.94127.94000
Minority Interest0000000000
Trade Payables61.4339.2729.3649.9217.2813.3713.5711.877.937.81
Others Liabilities 53.3728.8161.9766.9696.88179.47318.31760.48864.78970.12
Total Liabilities 645.79632.42646.35633.67909.06711.19692.56433.81417.32400.96

Fixed Assets

Net Fixed Assets +338.25328.41320.39298.59653.23634.13616.92356.49339.14321.81
Gross Block394.07401.58411.26413.31785.01785.02786.37786.36786.36786.36
Accumulated Depreciation55.8273.1690.86114.72131.78150.88169.45429.88447.22464.55
CWIP 0.04000000000
Investments 139.64139.64139.64139.23138.693.052.582.582.582.58
Inventories53.6436.2744.7650.6015.102.421.253.971.261.59
Trade Receivables68.1577.63116.56130.7185.1657.360.37000
Cash Equivalents 7.325.315.702.052.290.960.780.450.110.06
Others Assets 38.7445.1619.3012.4814.5813.2770.6670.3374.2474.92
Total Assets 645.79632.42646.35633.67909.06711.19692.56433.81417.32400.96

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21
Cash Flow From Operating Activity + -4.53-155.68-21.35-4.7831.37120.98148.38455.79112.37125.32
PBT -43.20-81.70-55.03-70.02-121.11-125.16-119.40-181.39-141.73-154.47
Adjustment 52.0359.5671.9483.0275.0793.18105.30165.86127.88143.75
Changes in Working Capital 25.83-91.3215.9841.4135.41152.97162.49471.32126.22136.05
Tax Paid 000-0-0-00000
Cash Flow From Investing Activity + -35.25-7.46-9.68-1.65-108.98-0.23-0.750.100.080.06
Capex -35.25-7.46-9.68-2.06-109.52-0-1.36000
Net Investments 0000.410-0.450.47000
Others 00000.540.220.140.100.080.06
Cash Flow From Financing Activity + 42.46161.1331.422.7877.85-120.63-147.91-455.79-112.43-125.44
Net Proceeds from Shares 1559.980000000
Net Proceeds from Borrowing 42.39158.5821.442.7847.85-46.75-61.56-231.80-2.480
Interest Paid 00000-73.94-86.34-96.05-109.96-125.44
Dividend Paid 0000000000
Others -14.93-2.4500300.060-127.9400
Net Cash Flow 2.67-2.010.39-3.640.240.12-0.280.090.01-0.05

Financial Ratio

PARTICULARSMar'12Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21
Ratios
ROE (%)-17.28-38.01-34.17-44.68-202.78N/AN/AN/AN/AN/A
ROCE (%)-0.71-7.04-0.14-1.91-11.02N/AN/AN/AN/AN/A
Asset Turnover Ratio0.350.30.30.290.20.060.050.060.070.03
PAT to CFO Conversion(x)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Working Capital Days
Receivable Days117.50137183.40244.80258.70494319.50000
Inventory Days98.5084.5076.5094.4078.7060.7020.3028.7029.9042.70
Payable Days185.40156.60118.7018399.60215727.20718.80571.70507.20

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *100.00100.00100.00100.0094.5194.5194.5194.5194.5194.50
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Parenteral Drugs (India) Ltd FAQs

The current trading price of Parenteral Drugs on 21-Aug-2023 18:01 is ₹3.39.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 20-Aug-2023 the market cap of Parenteral Drugs stood at ₹10.11 Cr

The latest P/E ratio of Parenteral Drugs as of 20-Aug-2023 is 0.00.

The latest P/B ratio of Parenteral Drugs as of 20-Aug-2023 is -0.01.

The 52-week high of Parenteral Drugs is ₹3.39 and the 52-week low is ₹3.08.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Parenteral Drugs is ₹8.50 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Parenteral Drugs (India) Ltd is a below average quality company.

The key valuation ratios of Parenteral Drugs (India) Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

No data found

About Parenteral Drugs (India) Ltd

Established in the year 1983, Parenteral Drugs has dedicated itself to the manufacturing of the best quality vital life saving drug at the lowest possible cost. Over the years, its path breaking innovation has led not only to lower costs but better quality as well because PDPL firmly believes that better quality dose not necessarily mean higher price, it can also be achieved by indigenous techniques and innovative technologies.

Commencing with production of I.V. fluids in polypropylene bottles for the first time ever, as against glass, PDPL has followed up the success in creating single use disposable eye drop It is now set to bring dialysis within the reach of the common man with its innovatively and indigenously made CAPD kits . The company went for a successful public issue in 1994. Using money merely as means to achieve an end, the company has very judiciously applied it to shape out to a reality from the blue print of the dreams of carefully identified areas of potent niche activities. A cost-effective technology at work is evident in every area of its varied production processes. In fact this is one of the rare companies which showcases the use of most modern state-of-the-art technologies co-existing in harmonious synergy with the labor intensive technologies and retained in larger societal interests.

Parenteral Drugs (India)  believes in appropriate and systematic methods and observes highest standard in  letter and spirit. Parenteral Drugs (India)’s quality standards are  truly  high. The company follows a stringent quality control policy, indeed takes quality control measures at every stage of the manufacturing process. The quality assurance department has a well equipped laboratory with most modern testing instrument. The quality policy has resulted in company being conferred upon the ISO 9001:2000 and WHO GMP certification by international bodies. Not just to the products at PDPL quality is pertinent to to every aspect pre-delivery service, delivery and post delivery service. It is a part of the people's attitude in every step from administration production to distribution.

PDPL is the pioneer company making 400 mg Ciprofloxacin infusion in 200 ml with 5% dextose. The I.V. fluids are packed in size ranging from 100 ml to 3 litre and dialysis solution up to 10 litres water for injection is manufactured with the help of hi-tech From-Fill-seal machine ranging from 1 ml to 10 ml.

Products manufactured by the company includes:

Solid and liquid orals

  • ANTIBIOTICS AND ANTIBACTERIAL
  • ANTIULCERANT
  • ANALGESICS ANTI-INFLAMMATORY
  • MULTIVITAMINS AND MINERALS
  • ANXIOLYTIC
  • ANTIPROTOZOAL
  • ANTICOLD
  • ANTHELMINTIC
  • ANTI-HISTAMINIC
  • MUSCLE RELAXANT
  • CARDIAC
  • ANTIDIABETIC
  • COUGH SYRUP
  • Appetite Enhancer

Injections

1. IV Fluids

  • Electrolytes
  • Antibacterial
  • Energy replenisher
  • Irrigation solution
  • Osmotic diuretic
  • Dialysis solution

2. Eye/ear drops

  • Cigram Drops
  • Gentate Drops
  • Gentate - B Drops
  • Ocuroid Drops
  • Flufen Eye Drops
  • Ikleen Eye Drops

Achievements/ recognition

  • The International Gold Awards.
  • The Udyog Ratna.
  • The company has recently achieved a major break-through in designing CAPD kits for patients with terminal renal failure.
  • Introduction of Ciprofloxacin 400 mg infusion in 200 ml with 5% Dextrose for the first time in our country.

Milestones

  • 1975- Founds Prem Pharmaceuticals (Leader in glass-filled I.V. fluids)
  • 1983- Establishes PDPL (Pioneering Leader in Polypropylene-filled I.V.fluids).
  • 1994- Successful public issue.
  • 1996-Launched First single Use Eye/Ear drop Dispensers using  FFS  technology
  • 1997- Establishes Royal Crystal Pvt. Ltd. [now Diamond Crystal-The only one to  make full lead Crystal Glassware in India]
  • 1998- Launched branded products in Tablets/Capsules/Liquids Orals/I.V.
  • 1998-Establishes Punjab Formulations.
  • 2001-Launched CAPD-the dialysis kit that's affordable by common man and is  superior to the import one.
You have 3 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: